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We previously reported a synthetic Laponite® crosslinked pNIPAM-co-DMAc (L-26 
pNIPAM-co-DMAc) hydrogel which promotes differentiation of mesenchymal stem 27 
cells (MSCs) to nucleus pulposus (NP) cells without additional growth factors. The 28 
clinical success of this hydrogel is dependent on: integration with surrounding tissue; 29 
the capacity to restore mechanical function; as well as supporting the viability and 30 
differentiation of delivered MSCs. Bovine NP tissue explants were injected with 31 
media (control), human MSCs (hMSCs) alone, acellular L-pNIPAM-co-DMAc 32 
hydrogel or hMSCs incorporated within the L-pNIPAM-co-DMAc hydrogel and 33 
maintained at 5% O2 for 6 weeks. Viability of native NP cells and delivered MSCs 34 
was maintained. Furthermore hMSCs delivered via the L-pNIPAM-co-DMAc hydrogel 35 
differentiated and produced NP matrix components: aggrecan, collagen type II and 36 
chondroitin sulphate, with integration of the hydrogel with native NP tissue. In 37 
addition L-pNIPAM-co-DMAc hydrogel injected into collagenase digested bovine 38 
discs filled micro and macro fissures, were maintained within the disc during loading 39 
and restored IVD stiffness. The mechanical support of the L-pNIPAM-co-DMAc 40 
hydrogel, to restore disc height, could provide immediate symptomatic pain relief, 41 
whilst the delivery of MSCs over time regenerates the NP extracellular matrix; thus 42 
the L-pNIPAM-co-DMAc hydrogel could provide a combined cellular and mechanical 43 
repair approach.    44 
Abbreviations 45 
LBP: low back pain; IVD: Intervertebral disc; CEP: cartilaginous end plate; AF: 46 
annulus fibrosus; NP: nucleus pulposus; ECM: extracellular matrix; MSCs: 47 
mesenchymal stem cells; hMSCs: human mesenchymal stem cells; L-pNIPAM-co-48 
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DMAc: Laponite® crosslinked pNIPAM-co-DMAc hydrogel; FCS: fetal calf serum, 49 
NIPAM: N-isopropylacrylamide; DMAc: N, N' –dimethylacrylamide; AIBN: 2-2'-50 
azobisisobutyronitrile; SEM: scanning electron microscopy; IHC: 51 
Immunohistochemistry. 52 
Keywords 53 
Intervertebral disc, Nucleus pulposus, Injectable hydrogel, Mesenchymal stem cells, 54 
Tissue explant culture. 55 
1. Introduction 56 
Low back pain (LBP) is an increasingly prevalent clinical condition that affects over 57 
80% of the population at some point during their lifetime [1]. The aetiology of chronic 58 
LBP is thought to be multifactorial; however, degeneration of the intervertebral disc 59 
(IVD) is regarded as a key attributing factor [2,3].  Morphologically the IVD can be 60 
divided into three distinct regional structures: the cartilaginous endplates (CEP); the 61 
annulus fibrosus (AF) and the central gelatinous nucleus pulposus (NP), rich in 62 
proteoglycans (mainly aggrecan) and collagen type II [4]. The IVD transmits load, 63 
facilitates a range of spinal movement and dissipates energy during motion [5]. 64 
Degeneration of the IVD is characterised by a number of progressive extracellular 65 
matrix (ECM) changes including altered matrix synthesis and increased degradation 66 
of normal matrix components [6], resulting in an overall reduction in the proteoglycan 67 
content of the NP [7]. This is mediated by the catabolic phenotype of degenerate NP 68 
cells [8,9] alongside decreased viability as well as increased apoptosis [17] and 69 
senescence of remaining NP cells [10]. This results in reduced NP tissue hydration 70 
and an overall loss in disc height [11], culminating in mechanical failure resulting in 71 
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abnormal stresses to surrounding spinal tissues and compression of nerve routes 72 
[12]. Consequently, the restoration of disc height is a key therapeutic target for the 73 
symptomatic relief of chronic LBP. 74 
New approaches in tissue engineering have led to the investigation of a variety of 75 
treatment options aimed at the restoration of disc height using acellular implants [13-76 
16], the use of regenerative cells [17-20] or the combined delivery of regenerative 77 
cells with supporting mechanical scaffolds [21,22]. Mesenchymal stem cells (MSCs) 78 
have been highlighted as an attractive cell choice since they have proliferative 79 
capacity, can be extracted from a variety of adult tissues and have the capacity to 80 
differentiate into NP like cells [19,20,23-25]. However, concerns remain regarding 81 
MSC leakage [26], as well as a lack of control over differentiation following injection 82 
[27], thus highlighting the potential need for cell carrier systems. The use of a 83 
combined approach is appealing, since it is hypothesised that the mechanical 84 
support of the biomaterial scaffold would provide immediate pain relief. Whilst the 85 
delivery of regenerative cells would provide a long term, gradual regeneration of an 86 
ECM which biologically functions, akin to native NP tissue. To date, a variety of 87 
biomaterial scaffolds have been investigated for repair of the NP. However injectable 88 
scaffolds with the potential to deliver cells, have not demonstrated the required 89 
mechanical robustness [14]. Whilst those developed as acellular NP replacement 90 
scaffolds have so far failed, due to poor integration resulting in extrusion or expulsion 91 
of the implanted material [14,28,29] or are unable to deliver regenerative cells to the 92 
IVD [13-16]. The implantation methodology is also an important consideration to 93 
minimise trauma to the existing IVD tissue [30,31]. 94 
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We have previously reported the development of a synthetic Laponite® crosslinked 95 
pNIPAM-co-DMAc (L-pNIPAM-co-DMAc) hydrogel delivery system which has the 96 
potential to deliver human MSCs (hMSCs) via minimally invasive injection, using 97 
small bore needles (26G) which decrease the chance of inducing damage to the 98 
annulus fibrosus [23]. We have demonstrated in vitro that hMSCs incorporated into 99 
L-pNIPAM-co-DMAc hydrogels and cultured in 5% O2, differentiated into NP-like 100 
cells, without the use of chondrogenic inducing medium or additional growth factors 101 
[23]. The clinical success of this hydrogel is dependent on: integration with 102 
surrounding tissue; the capacity to restore mechanical function; as well as supporting 103 
the viability and differentiation of delivered MSCs.  104 
In the present study, we investigated the efficacy of several IVD repair strategies 105 
including: hMSCs alone, acellular L-pNIPAM-co-DMAc hydrogel or hMSCs 106 
incorporated within L-pNIPAM-co-DMAc hydrogel, injected into bovine NP tissue 107 
explants. This study tested the hypothesis that the delivery of hMSCs within the L-108 
pNIPAM-co-DMAc hydrogel would aid scaffold integration, and promote 109 
differentiation of MSCs towards the correct NP cell phenotype within native NP 110 
tissue. We additionally investigated the mechanical function, defined in this study as 111 
disc apparent modulus, strain under load, energy dissipation, and restoration of 112 
hydrogel injected bovine IVDs following collagenase digestion. Together these 113 
investigations determine the capacity of this hydrogel to be used as both a cell 114 
delivery vehicle and as a mechanical support scaffold in the treatment of IVD 115 
degeneration. 116 
2. Materials and Methods 117 
2.1. Nucleus pulposus tissue explant culture 118 
6 
 
Bovine tails from 9 months old to 18 months old cows were obtained from the 119 
abattoir. Caudal IVDs were excised and NP tissue was isolated. Cores of NP tissue 120 
(0.5cm in diameter) were formed and placed in a Perspex® ring, in sterile 6 well 121 
culture plates, as previously described [17].  Ten millilitres of DMEM media (Life 122 
Technologies, Paisley UK) supplemented with 10% v/v heat inactivated foetal calf 123 
serum (FCS) (Life Technologies, Paisley UK), 100U/ml penicillin (Life Technologies 124 
Paisley UK), 100g/ml streptomycin (Life Technologies Paisley UK), 250ng/ml 125 
amphotericin (Sigma, Poole UK), 2mM glutamine (Life Technologies, Paisley UK) 126 
and 10g/ml ascorbic acid (Sigma, Poole UK) (complete cell culture media) was 127 
applied and tissue explants and were maintained in culture for 48 hours prior to 128 
hMSC and hydrogel injection.  129 
2.2. Hydrogel synthesis 130 
An exfoliated suspension of Laponite® clay nanoparticles (25-30nm diameter, <1nm 131 
thickness) (BYK Additives Ltd, Cheshire UK) was prepared by vigorous stirring of 132 
Laponite  (0.1g) in deionised H20 (10ml) (18 MΩ) for 24 hours.  N-133 
isopropylacrylamide 99% (NIPAM) (0.783g) (Sigma, Poole UK), N, N' -134 
dimethylacrylamide (DMAc) (0.117g) (Sigma, Gillingham UK) and 2-2'-135 
azobisisobutyronitrile (AIBN) (0.009g) (Sigma, Poole UK) were added to the 136 
suspension and stirred for 1 hour. After passing the suspension through a 5-8µm 137 
pore filter paper, polymerisation was initiated by heating to 80ºC and the reagents 138 
were allowed to react for 24 hours. Following 24 hours the hydrogel suspension was 139 
cooled to 38-39oC prior to cell incorporation. Further cooling of the polymeric 140 
suspension to 37oC, i.e. below the lower critical solution temperature (LCST), 141 




2.3. Mesenchymal stem cell source, expansion and transfer to nucleus 144 
pulposus tissue explants. 145 
Commercial bone marrow derived human adult mesenchymal stem cells (hMSCs) 146 
extracted from a 39yr old donor (Lonza, Slough UK) were cultured in complete 147 
DMEM media (Life Technologies, Paisley UK). MSCs were expanded in monolayer 148 
culture to passage 7 to ensure sufficient cells were available. To allow cell tracking 149 
following injection, the MSCs were labelled with a fluorescent intracellular 150 
carboxyfluorescein N-hydroxysuccinimidyl ester (CFSE) cell labelling kit, (Abcam, 151 
Cambridge, UK) according to manufacturer's instructions. Cell seeding solutions 152 
were prepared at a density of 4x106 cells/ml in either complete DMEM media or 153 
liquid hydrogel suspension (38-39oC) and then 50µl injected into the centre of NP 154 
tissue explants via 26 gauge needle injection (Becton Dickinson, Plymouth, UK). 155 
Fifty microliters of media or hydrogel suspension containing no cells was also 156 
injected via a 26 gauge needle (Becton Dickinson, Plymouth, UK) into NP tissue 157 
explants. This gave four experimental groups: media injected control (control), hMSC 158 
injected alone (hMSC), acellular L-pNIPAM-co-DMAc hydrogel (acellular Hy) and 159 
hMSC incorporated within L-pNIPAM-co-DMAc hydrogel (hMSC + Hy) injected NP 160 
tissue explants. All NP tissue explants were cultured in complete DMEM cell culture 161 
media via careful overlay of 10ml of media per NP tissue explant, incubated at 37oC, 162 
5% CO2 and maintained in culture for up to 6 weeks in an oxygen controlled glove 163 
box (Coy Lab products, York, UK) at 5% O2. Media was replaced every 2-3 days. 164 
Samples were removed after 48 hours, 2, 4 and 6 weeks for analysis of cell viability, 165 
scanning electron microscopy (SEM), histological assessment of matrix deposition 166 
and NP cell phenotype analysis using immunohistochemistry (IHC).  167 
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2.4. Cytospins 168 
IHC was performed on MSCs taken from monolayer culture prior to injection into NP 169 
tissue explants to serve as time zero controls. Monolayer cells were trypsinised and 170 
cells fixed in 4% w/v paraformaldehyde/PBS (Sigma, Poole UK) for 20min, spun at 171 
300g for 5 min to form a cell pellet and resuspended in PBS to a cell density of 300 172 
cells per microlitre. One hundred microlitres of cell suspension was then cytospun, 173 
formed via centrifugation at 1000rpm for 3 min (Shandon Cytospin 3, Thermo 174 
Scientific, Loughborough UK). Slides were subsequently air-dried and stored at 4oC 175 
until required for IHC analysis. 176 
2.5. Processing of tissue explants and identification of the injection site: 177 
Triplicate NP tissue explants of each experimental group: control, hMSC alone, 178 
acellular Hy and hMSC + Hy, were fixed in 10% w/v formalin (Leica Microsystems, 179 
Milton Keynes UK) overnight prior to routine paraffin embedding. Tissue samples 180 
were serially sectioned at 4µm, perpendicular to the needle injection, and two 181 
sections every 100µm were mounted onto positively charged slides (Leica 182 
Microsystems, Milton Keynes UK). Sections were air-dried, dewaxed in Sub-X (Leica 183 
Microsystems, Milton Keynes UK), dehydrated in industrial methylated spirit (IMS) 184 
(Fisher, Loughborough UK), washed in deionised H2O and then stained with either 185 
routine haematoxylin and eosin (H&E) (Leica Microsystems, Milton Keynes UK) 186 
histological staining or Hoechst nuclear fluorescent staining (Sigma, Poole UK). 187 
Slides stained for H&E were immersed in Mayers haematoxylin for 2 minutes, rinsed 188 
in water for 5 minutes, immersed in eosin for 2 minutes, dehydrated in IMS, cleared 189 
in Sub-X and mounted in Pertex® (Leica Microsystems, Milton Keynes UK). Slides 190 
stained with Hoechst were immersed in 5pg/mL Hoechst/PBS, incubated for 10min, 191 
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washed 3 times in PBS and mounted in 90% v/v glycerol/PBS. Slides were then 192 
visualised using light and fluorescent microscopy with an Olympus BX51 microscope 193 
and images captured by digital camera and Capture Pro OEM v8.0 software (Media 194 
Cybernetics, Buckinghamshire, UK) to identify the injection site and distinguish 195 
native NP cells (Hoechst+/CFSE-) and injected hMSCs (Hoechst+/CFSE+). Within 196 
control NP explants, the injection site was identified where the needle track could be 197 
seen histologically (within early time points) or halfway through the entire depth of 198 
the NP tissue explant. Where MSCs were injected alone injection site was 199 
determined via the identification of CFSE positive cells. Where acellular L-pNIPAM-200 
co-DMAc or L-pNIPAM-co-DMAc with incorporated MSCs had been injected, the 201 
injection site was determined by the histological identification of the hydrogel. 202 
Following identification of the position of the injection site and the presence of CFSE 203 
positive cells, serial sections in the area of the injection site were mounted onto 204 
positively charged slides: for caspase 3 IHC to identify the presence of apoptotic 205 
cells, histological assessment of matrix components using Alcian blue and Masson 206 
trichrome as well as IHC for aggrecan, chondroitin sulphate and collagen type II to 207 
assess phenotypic characteristics.  208 
2.6. Structural and Mechanical Characterisation 209 
2.6.1. Scanning electron microscopy (SEM). 210 
Samples were removed from culture after 48 hours and 6 weeks, frozen at -80oC 211 
and subsequently freeze dried using a FD-1A-50 freeze drier set to -53˚C, 3.8 x 10-4 212 
mbar overnight. The sample was then fractured to expose the interior surface 213 
morphology attached onto an aluminium stub and then using a Quorum Technology 214 
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150 Q TES system coated with gold (10µA sputter current for 180 seconds with a 2.7 215 
tooling factor) for imaging. 216 
The fractured surfaces were examined using a FEI NOVA nanoSEM 200 scanning 217 
electron microscope (SEM). Secondary electron images were obtained using 218 
accelerating voltage 5KV at various magnifications ranging from 1000x to 40,000x.  219 
2.6.2. Hydration degree 220 
To evaluate the hydration degree of NP tissue explants, samples were extracted 221 
from culture in triplicate following 48 hours, 2, 4 and 6 weeks and the wet weight (M0) 222 
of the NP tissue explants was measured. Samples were then freeze dried using a 223 
FD-1A-50 freeze drier set to -53 ˚C, 3.8 x 10-4 mbar overnight to obtain the dry 224 
weight (Mt). The hydration degrees of the NP tissue explants were calculated using 225 
eq1: 226 
�ݕ݀����݋݊ ݀݁��݁݁ = ሺM0 − M�ሻM0  ݔͳͲͲ 
(1) 227 
2.6.3. Dynamic mechanical analysis  228 
The mechanical properties of NP tissue explants were characterised following 6 229 
weeks in culture. Replicate samples were removed from culture, blotted and their 230 
mechanical properties characterised by DMA. Samples were trimmed using a 5mm 231 
circumference circular biopsy punch from the centre of NP tissue explants, all 232 
sample heights were measured and recorded using digital callipers prior to 233 
measurement. Triplicate samples were analysed using a PerkinElmer DMA8000 234 
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model under confined compression mode at 25 °C, applying a sinusoidal force with a 235 
0.02mm displacement at 2.5Hz. 236 
2.7. Histological evaluation of matrix components  237 
Matrix deposition around the injection site of NP tissue explants was investigated 238 
following 48 hours, 2, 4 and 6 weeks in triplicate. Sections were dewaxed in Sub-X, 239 
dehydrated in IMS, washed in deionised H2O and then stained using histological 240 
stains: 1% w/v Alcian blue (pH 2.5) (Sigma Aldrich, Poole  UK) in 3% v/v acetic acid 241 
(Sigma Aldrich, Poole  UK) for 5 minutes with 1% Neutral red w/v (Sigma Aldrich, 242 
Poole  UK) used as a counter stain for 2 minutes or Masson trichrome (Bio-Optica, 243 
Miller & Miller (Chemicals) Ltd, Hainault UK) according to the manufacturer’s 244 
instructions. Sections were dehydrated in IMS, cleared in Sub-X and mounted in 245 
Pertex® (Leica Microsystems, Milton Keynes UK). All slides were examined with an 246 
Olympus BX51 microscope and images captured by digital camera and Capture Pro 247 
OEM v8.0 software (Media Cybernetics, Buckinghamshire, UK). Histological sections 248 
were analysed, features noted and images captured to document their histological 249 
appearance.  250 
2.8. Immunohistochemistry assessment of apoptosis and phenotypic 251 
characteristics.  252 
Caspase 3 as a marker of apoptosis and NP matrix markers: aggrecan, collagen 253 
type II and chondroitin sulphate were selected for immunohistochemistry (IHC) to 254 
assess the viability and phenotypic characteristics of NP tissue explants and 255 
delivered hMSCs. IHC was performed as previously described [32]. Briefly, 4μm 256 
paraffin sections were de-waxed, rehydrated and endogenous peroxidase-blocked 257 
using hydrogen peroxide (Sigma, Aldrich Poole UK). After washing in tris-buffered 258 
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saline (TBS; 20 mM tris, 150 mM sodium chloride, pH 7.5) sections were subjected 259 
to antigen retrieval methods (Table I). Following TBS washing, nonspecific binding 260 
sites were blocked at room temperature for 90 minutes with 25% w/v serum (Abcam, 261 
Cambridge, UK) (Table I) in 1% w/v bovine serum albumin in TBS. Sections were 262 
incubated overnight at 4°C with the appropriate primary antibody (Table I). Negative 263 
controls in which mouse or rabbit IgGs (Abcam Cambridge UK) replaced the primary 264 
antibody at an equal protein concentration were used (Table I). After washing in 265 
TBS, sections were incubated in 1:500 biotinylated secondary antibody (Table I). 266 
Disclosure of secondary antibody binding was by the HRP-streptavidin biotin 267 
complex (30 minute incubation) (Vector Laboratories, Peterborough, UK), TBS 268 
washing, followed by application of 0.08% v/v hydrogen peroxide in 0.65 mg/ml 3,3'-269 
diaminobenzidine tetrahydrochloride (Sigma Aldrich, Poole UK) in TBS (20 minute 270 
incubation). Sections were counterstained with Mayer’s haematoxylin, dehydrated in 271 
IMS, cleared in Sub-X and mounted in Pertex®. All slides were visualised using an 272 
Olympus BX51 microscope and images captured by digital camera and Capture Pro 273 
OEM v8.0 software (Media Cybernetics, Buckinghamshire, UK). Evaluation of 274 
caspase 3 IHC staining was performed by counting immunopositive and 275 
immunonegative cells for each section and immunopositive cells expressed as a 276 
percentage of the total count. Images were captured for IHC staining of NP markers: 277 
aggrecan, collagen type II and chondroitin sulphate to qualitatively analyse the 278 





















Table I: Target antibodies used for IHC, their optimal concentrations and antigen 280 
retrieval methods. Heat antigen retrieval consisted of 10-minute microwave 281 
irradiation in 0.05M tris buffer, pH 9.5 pre-heated to 60˚C. Enzyme antigen retrieval 282 
consisted of 30-minute incubation in TBS; 20 mM tris, 150 mM sodium chloride, 283 
46.8mM calcium chloride dihydrate pH 7.5, containing 0.01% w/v α-chymotrypsin 284 
from bovine pancreas at 37oC.  285 
 286 
2.9 Mechanical characterisation of L-pNIPAM-co-DMAc hydrogel injected 287 
whole bovine IVDs. 288 
2.9.1. IVD Isolation and Collagenase Digestion 289 
Bovine tails from 9 to 18 month old cows were obtained from the abattoir, operating 290 
in concordance with animal welfare regulations. Tails were stored at -20°C shortly 291 
post sacrifice and tested a maximum of one month post storage. Tails were thawed 292 
at 5°C for 24 hours prior to sample preparation. Discs were dissected whole from tail 293 
sections between cd1-2 and cd4-5. Discs without parallel faces or with visible signs 294 
of damage were discarded. The remaining discs were allowed to equilibrate to room 295 
temperature for 12 hours before testing, between 2 and 4 discs were gained from 296 
each tail section. Discs were stored in airtight sealed bags to prevent dehydration 297 
during this time. Discs were randomly assigned to four test groups (n=10 per group): 298 
healthy; sham injected; collagenase digested and collagenase digested following 299 
hydrogel injected. Healthy discs were not experimentally manipulated following 300 
excision, sham injected discs were stabbed with a 21-gauge needle to assess the 301 

















injected with 100-200µl of a 2mg/mL collagenase solution (Sigma, Poole, UK) in 303 
distilled water (injection was performed until either the internal pressure in the disc 304 
prevented any further injection or a maximum of 200µl had been injected) and 305 
incubated for 2 hour at 37oC. 306 
2.9.2 Injection of L-pNIPAM-co-DMAc hydrogel in whole bovine IVDs 307 
Following collagenase digestion, discs to be injected with hydrogel were inspected 308 
morphologically to ensure collagenase digestion had successfully induced void 309 
formation. Hydrogel injected discs then received an injection of 50-200µL of acellular 310 
L-pNIPAM-co-DMAc hydrogel, with an incorporated green food dye for visulisation. 311 
Hydrogel injected discs were left 30 minutes post injection to allow the L-pNIPAM-co-312 
DMAc hydrogel to stabilize and mimic the operation time for the patient, prior to 313 
testing. Injection protocol consisted of the syringe being depressed until either the 314 
internal pressure in the disc prevented any further intake or a maximum of 200µl of 315 
L-pNIPAM-co-DMAc hydrogel had been injected. All the needle tips were inserted 316 
into the centre of the NP before injection of material. Visual inspection during 317 
injection allowed needle position to be observed through the deformation of 318 
surrounding material. 319 
2.9.3. Mechanical loading of IVDs 320 
Discs were loaded cyclically using a dynamic test rig incorporating a hydraulic piston 321 
controlled by Wavematrix 1.8 test software and a Labtronic 8800 hydraulic controller 322 
(Instron. Mass, USA). Discs were placed between two smooth parallel metal platens 323 
without further constraint. Discs with non-parallel surfaces were rejected prior to 324 
testing and no lateral movement was observed during testing (indicating that disc 325 
surfaces were parallel and all deflection was in the axial direction). Discs were 326 
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subjected to a sinusoidal load between 0.53 and 0.65 MPa at 2 Hz to simulate 327 
walking based on known values from the literature [51-53]. Each disc was ramped to 328 
a preload at the midpoint between the upper and lower boundaries at a rate of 0.01 329 
kN/s, immediately upon reaching the preload, cyclic loading was applied for 100 330 
seconds, representative of a short period of activity typical of activities of daily living 331 
(ADLs) in all but the most severely impaired persons. 332 
Three measures of mechanical response were tracked by the data acquisition tools 333 
connected to Wavematrix. Engineering stiffness of each disc was measured as the 334 
change in force divided by the change in displacement from minimum (Fmin = 0.53 335 
MPa x disc cross-sectional area) to maximum (Fmax = 0.65 MPa x disc cross-336 
sectional area) loading. Strain was measured as the displacement between those 337 
points divided by the disc height at minimum loading. Lastly the energy dissipated by 338 
discs during each loading/unloading cycle was calculated from the hysteresis in the 339 
load deflection data. 340 
 341 
2.10. Data processing and statistical analysis 342 
All tests were performed at least in triplicate. Data was assessed for normality using 343 
the Shapiro Wilks test and found to be non-parametric and hence statistical 344 
comparisons were performed by Kruskal-Wallis with a pairwise comparisons 345 
(Conover-Inman) post hoc test performed with statistical significance accepted at 346 
p≤0.05. Pairwise comparisons were made as follows: between all-time points and 347 
between the different experimental groups for caspase 3 immunopositivity; between 348 
the different experimental groups for mechanical analysis; hMSC alone, Acellular Hy 349 
and hMSC + Hy compared with media injected control NP explants for hydration 350 
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assessment at each given time point. Data was then presented on graphs; all 351 
replicates have been shown with median value indicated to demonstrate clearly the 352 
spread of replicates.  353 
 354 
3. Results  355 
3.1. Identification of injected L-pNIPAM-co-DMAc hydrogel and mesenchymal 356 
stem cells. 357 
No CFSE (green) positive cells were identified within media injected controls or 358 
acellular hydrogel injected NP tissue explants (Fig 1). CFSE positive MSCs were 359 
identified where MSCs had been injected alone, where they remained in clusters at 360 
the vicinity of the injection site following 4 weeks in culture (Fig 1). Some CFSE 361 
positive cells appeared to have migrated away from the injection site following 6 362 
weeks, although many were still in close proximity to each other (Fig 1). Infiltrating 363 
native NP cells stained with Hoechst were identified within the acellular L-pNIPAM-364 
co-DMAc following 4 and 6 weeks in culture (Fig 1). CFSE positive MSCs were 365 
identified within the L-pNIPAM-co-DMAc hydrogel throughout the 6 week culture 366 
duration where they had been incorporated prior to injection (Fig 1). CFSE positive 367 
MSCs were also observed within the native NP tissue surrounding the hydrogel 368 
region following 6 weeks in culture (Fig 1).   369 
 370 
3.2. Caspase 3 cell viability. 371 
Low levels of apoptosis was observed in media injected control NP explant tissue, 372 
with no significant difference in the number of caspase 3 immunopositive cells 373 
throughout the 6 week culture duration (Fig 2a,b). Where acellular L-pNIPAM-co-374 
DMAc hydrogel had been injected no significant difference in the number of caspase 375 
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3 immunopositive cells was observed between native NP cells within the surrounding 376 
NP tissue compared with native NP cells infiltrated within the hydrogel (Fig 2a,b). 377 
Low levels of apoptosis within MSCs injected alone, with no significant difference in 378 
the number of immunopositive cells observed throughout the 6 week culture duration 379 
(Fig 2a,b). Where MSCs were incorporated within L-pNIPAM-co-DMAc hydrogel 380 
prior to injection, no significant difference in the number of caspase 3 381 
immunopositive cells was observed between cells found within the surrounding 382 
native NP tissue and cells found within the L-pNIPAM-co-DMAc hydrogel itself (Fig 383 
2a,b). No significant difference in the number of capsase 3 immunopositive cells was 384 
observed between the different experimental groups at any time point (Fig 2a,b) 385 
(P>0.05).  386 
 387 
3.3. Structural and mechanical characterisation 388 
3.3.1. Scanning electron microscopy 389 
The interior micro scale morphology of NP tissue explants was examined using 390 
scanning electron microscopy (SEM) (Fig 3). Native NP cells were visualised 391 
embedded within a disorganised fibrous collagen matrix, throughout the 6 week 392 
culture duration in media injected control explants (Fig 3). Where MSCs were 393 
injected alone clustered cells could be seen following 48 hours which appeared to 394 
have migrated following 6 weeks in culture (Fig 3). Injected acellular L-pNIPAM-co-395 
DMAc hydrogel displayed a comparatively uniform interconnecting porous network 396 
encapsulated by the surrounding NP tissue following 6 weeks in culture. Where 397 
MSCs were incorporated within the L-pNIPAM-co-DMAc hydrogel prior to injection, 398 
cells could be seen within the centre of the hydrogel region (Fig 3); a distinction in 399 
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the microscale morphology of the interior hydrogel was still evident in comparison to 400 
the native surrounding NP tissue following 6 weeks, however integration could be 401 
seen at the hydrogel/NP tissue interface with connecting NP tissue fibres penetrating 402 
within the outside edges of the hydrogel region (Fig 3). 403 
 404 
3.3.2. Dynamic mechanical analysis 405 
MSC injected and hydrogel injected NP tissue explants displayed similar mechanical 406 
properties to media injected control explants with no significant difference in the 407 
elastic modulus (G'), loss modulus (G") or tan delta (tan�) for any of the experimental 408 
groups following 6 weeks in culture (Fig 4a,b,c).  409 
 410 
3.3.3. Hydration assessment 411 
The injection of MSCs alone did not significantly alter the hydration degree of NP 412 
tissue explants following 48 hours, 4 and 6 weeks in culture, although a significant 413 
increase (P=0.0011) in the hydration of hMSC injected alone NP tissue explants was 414 
observed in comparison to media injected control explants following 2 weeks in 415 
culture (Fig 4d). Where acellular L-pNIPAM-co-DMAc hydrogel was injected a 416 
significant increase (P=0.0064) in the hydration degree was observed in comparison 417 
to media injected control explants following 6 weeks in culture (Fig 4d). Where 418 
hMSCs were incorporated into L-pNIPAM-co-DMAc hydrogel prior to injection a 419 
significant increase in the hydration degree was observed in comparison to media 420 
injected control explants following 2 (P=0.0015) and 6 (P=0.0095) weeks in culture in 421 




3.4. Histological evaluation of matrix components 424 
Reduced matrix staining for both proteoglycans, and collagen was observed 425 
throughout the 6 week culture period within media injected control NP explants (Fig 426 
5). Where MSCs were injected alone, blue staining for proteoglycans was present 427 
within and surrounding the cell clusters, although the staining intensity was less than 428 
that of the native surrounding NP tissue (Fig 5). Areas of blue staining for collagen 429 
were also observed within cell clusters where MSCs had been injected alone, 430 
although the majority of cells present within the clusters were negative (red) for 431 
collagen staining (Fig 5). Positive blue matrix staining for both proteoglycans and 432 
collagen was observed within the acellular L-pNIPAM-co-DMAc hydrogel which had 433 
been injected into NP explants, particularly following 4 and 6 weeks (Fig 5). A distinct 434 
native NP tissue border, with high intensity collagen staining, was observed 435 
surrounding the acellular L-pNIPAM-co-DMAc hydrogel following 48 hours, 2 and 4 436 
weeks in culture (Fig 5). Blue positive proteoglycan and collagen producing cells 437 
were observed within the L-pNIPAM-co-DMAc hydrogel where hMSCs had been 438 
incorporated prior to injection throughout the 6 week culture duration (Fig 3). Native 439 
NP tissue directly adjacent to L-pNIPAM-co-DMAc hydrogel with incorporated 440 
hMSCs, demonstrated strong intensity staining for both proteoglycans and collagen 441 
(Fig 5). A distinct NP tissue border, with high intensity collagen staining, was present 442 
surrounding the L-pNIPAM-co-DMAc hydrogel, where MSCs were incorporated, 443 
following 48 hours and 2 weeks in culture, however this was subsequently absent 444 
with integration of the surrounding NP tissue within the hydrogel observed following 445 




3.5. Immunohistochemical evaluation of cell phenotype 448 
Immunohistochemistry was used to assess the expression and localisation of the NP 449 
matrix markers collagen type II, aggrecan and chondroitin sulphate within MSCs, 450 
both in monolayer and following injection into NP tissue explants, as well as within 451 
native NP cells within the explant tissue (Fig 6). Collagen type II, aggrecan and 452 
chondroitin sulphate was expressed by all native NP cells found with control, 453 
acellular L-pNIPAM-co-DMAC injected, hMSC only injected and hMSC incorporated 454 
within L-pNIPAM-co-DMAc injected NP tissue explants, throughout the 6 week 455 
culture duration (Fig 6). Immunopositive cells for collagen type II, aggrecan and 456 
chondroitin sulphate were identified surrounding the acelllular L-pNIPAM-co-DMAc 457 
hydrogel following 48 hours, 2 and 4 weeks in culture, with some immunopositive 458 
native NP cells for collagen type II, aggrecan and chondroitin sulphate observed 459 
within the acellular L-pNIPAM-co-DMAc hydrogel following 6 weeks in culture (Fig 6).  460 
Monolayer MSCs extracted from culture prior to injection into NP tissue explants 461 
showed no immunopositivity for aggrecan, with low levels of immunopositivity for 462 
chondroitin sulphate (average 52% range 50-55%) and collagen type II (average 463 
17% range 14-20%) (Suppl Fig 1). Immunopositive cellular and matrix staining for 464 
collagen type II, aggrecan and chondroitin sulphate was observed within the vicinity 465 
of the cell clusters where hMSCs had been injected alone, from 48 hours to 6 weeks 466 
in culture (Fig 6). Intense matrix staining and positive cellular staining for collagen 467 
type II, aggrecan and chondroitin sulphate was observed within the L-pNIPAM-co-468 
DMAc hydrogel where MSCs had been incorporated prior to injection (Fig 6). NP 469 
tissue with high intensity matrix staining for collagen type II and chondroitin sulphate 470 
was present integrating within the L-pNIPAM-co-DMAc hydrogel where MSCs had 471 
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been incorporated prior to injection, following 6 weeks in culture (Fig 6). All IgG 472 
control sections for collagen type II, aggrecan and chondroitin sulphate showed no 473 
immunopositivity (suppl Fig 1).  474 
3.6. Mechanical Characterisation of L-pNIPAM-co-DMAc hydrogel injected 475 
Whole Bovine IVD. 476 
Whole bovine IVDs subjected to loading simulating a short period of walking 477 
demonstrated a different mechanical response depending on the treatment regime of 478 
the disc. When differences in disc size were accounted for and outliers excluded 479 
healthy discs had 1.88 times higher stiffness (24.3 to 12.9 MPa) (Fig7A), 80% lower 480 
strain (0.54% to 2.7%) (Fig 7B) and 2.8 times greater energy dissipation (2.12 to 481 
0.76 J/cycle) (Fig 7C) compared to discs that had undergone collagenase digestion, 482 
with P<0.001 in each case when outliers were accounted for (Fig 7). Discs subjected 483 
to collagenase digestion could be seen in 6 out of 10 discs to display clear digestion 484 
of the IVD (Fig 7) with alteration to mechanical properties, however 4 discs which 485 
were injected with collagenase failed to show evidence of digestion (no voids visible) 486 
and thus were removed from the statistical analysis and showed as red outliers (Fig 487 
7). Discs subjected to the same collagenase treatment process following observation 488 
of clear evidence of digestion morphologically were subsequently injected with L-489 
pNIPAM-co-DMAc hydrogel, these discs demonstrated a complete recovery of disc 490 
stiffness, displaying only non-significant (P>0.05) differences from healthy disc 491 
stiffness (24.3 to 26.4 MPa) (Fig 7A) and strain values (0.54% to 0.5%) (Fig 7B). 492 
However there was no recovery of the discs ability to dissipate energy (Fig7C), with 493 
hydrogel injected discs dissipating less energy than any other test group (0.40 494 
J/cycle), significantly (P < 0.001) lower than even collagenase digested discs (Fig 7c). 495 
Discs injected with hydrogel containing green dye could be clearly identified 496 
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macroscopically (Fig 7D,E) and microscopically were shown to fill the fissures 497 
formed via collagenase digestion (Fig 7F,G).  498 
  499 
4. Discussion 500 
4.1. Evaluation of biological performance to act as a cell delivery vehicle. 501 
The clinical translation of hydrogels specifically developed for the delivery of 502 
regenerative cells to the IVD is dependent on several requirements: that they can be 503 
administered by a minimally invasive procedure that delivers the required cell 504 
population without detrimental effects to both the implanted cells and surrounding 505 
tissues during delivery. That they are biocompatible and thus support the viability of 506 
delivered cells and native cell populations. The hydrogel should facilitate cellular 507 
migration to aid in the integration with surrounding tissue to prevent biomaterial 508 
extrusion. Finally, the hydrogel should support and promote the differentiation of 509 
delivered MSCs into biologically functional NP like cells in order to repair and 510 
regenerate a matrix akin to native NP tissue.  511 
4.1.2. Minimally Invasive delivery of L-pNIPAM-co-DMAC hydrogel 512 
In our previous in vitro studies we have demonstrated that hMSC could be 513 
incorporated into liquid L-pNIPAM-co-DMAc hydrogel, injected through a narrow 26-514 
gauge needle before solidification at 37oC with no detriment to cell viability [23,33]. 515 
Here, acellular L-pNIPAM-co DMAc hydrogel was injected through the AF into 516 
collagenase digested bovine IVD via 26-gauge needle injection. The hydrogel was 517 
maintained within the disc during mechanical loading and shown histologically to 518 
infiltrate micro and macro fissures akin to those which could occur during IVD 519 
23 
 
degeneration. The selected needle diameter is an important design consideration 520 
which is often dictated by the viscosity of the biomaterial being injected [34]. It is 521 
generally accepted that the needle diameter should be as narrow as possible to 522 
avoid structural and mechanical damage to surrounding tissues during injection. 523 
However decreasing the needle diameter for viscous biomaterials increases injection 524 
pressures which can increase shear forces on cells reducing cell viability [34,35]. 525 
The low viscosity (0.97MPas at 54oC) [23] of the L-pNIPAM-co-DMAC liquid hydrogel, 526 
enabled its injection with incorporated hMSCs into NP tissue explants with no loss in 527 
viability. The minimally invasive route demonstrated here offers significant advantage 528 
over previously developed hydrogels implanted into IVD tissue where nucleotomy 529 
was required to create a void for the biomaterial to occupy [13-16,36], or large 530 
diameter surgical implanting tools were used [37]. Moreover, the synthetic route 531 
utilised, which exploits the thermal phase transition of a fully reacted polymer in the 532 
liquid state, offers rapid solidification at 37oC. This maintains the L-pNIPAM-co-533 
DMAC hydrogel and incorporated hMSCs within the injection site, whilst avoiding the 534 
need for additional implantation devices to initiate in situ polymerisation such as 535 
those proposed for photopolymerised hydrogels [15,25,34].  536 
4.1.3. Biocompatibility of L-pNIPAM-co-DMAc hydrogel. 537 
The biocompatibility of delivered hMSCs is essential if the repopulation of cells for 538 
the long term recovery and regeneration of a functional NP matrix is to be a viable 539 
therapeutic option in the treatment of IVD degeneration. In agreement with previous 540 
studies [17,20,38-42], excellent viability across all time points and all treatment 541 
regimes were observed. However, despite mimicking the hypoxic disc 542 
microenvironment, it should be noted that the culture conditions used in this study do 543 
not completely reflect that of the native IVD in terms of a mechanically loaded 544 
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environment [43] and low nutrient supply [44]. Moreover, the degenerate IVD is an 545 
extremely hostile biological environment with increased production of matrix 546 
degrading enzymes [6] and pro-inflammatory cytokines [8,9] which may affect 547 
viability in vivo. Future investigations to ascertain the survival of delivered MSCs 548 
within such conditions is paramount to the clinical translation of this kind of therapy. 549 
However the survival of MSCs incorporated within the L-pNIPAM-co-DMAc hydrogel, 550 
is extremely promising since the use of the hydrogel as a delivery system also 551 
provides the opportunity to simultaneously deliver antagonists of catabolic mediators 552 
if required.  553 
4.1.4. Integration of L-pNIPAM-co-DMAc hydrogel. 554 
The infiltration of native NP cells, demonstrated in both acellular and hMSC 555 
incorporated within the L-pNIPAM-co-DMAc hydrogel injected into NP explants, is 556 
particularly important to aid in scaffold integration with the surrounding NP tissue, to 557 
restore optimum mechanical function and prevent issues such as biomaterial 558 
extrusion [14,45].  Integration of L-pNIPAM-co-DMAC hydrogel with surrounding NP 559 
tissue was particularly evident in this study, with deposited matrix penetrating within 560 
the hydrogel/tissue interface shown histologically and using SEM. Despite initial 561 
fibrous encapsulation observed surrounding the hydrogel following 4 weeks  in 562 
acellular L-pNIPAM-co-DMAc hydrogel injected NP tissue explants, it is 563 
hypothesised that dynamic culture under mechanical load would promote and 564 
accelerate the hydrogel tissue integration, as dynamic compressive mechanical 565 
loading has been shown to promote NP matrix biosynthesis [46], increase NP cell 566 
metabolism [46,47] and promote proliferation and differentiation of MSCs into NP-like 567 
cells [48,49]. 568 
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4.1.5. Differentiation of MSCs following Injection into NP tissue explants 569 
In agreement with previous studies [17], where MSCs were injected alone into NP 570 
tissue explants, the cells were maintained within clusters at the vicinity of the 571 
injection site for up to 4 weeks, although migration was evident following 6 weeks in 572 
culture. Migration and differentiation of these cells into NP like cells is essential for 573 
efficacious NP matrix repair. Here MSCs injected alone were shown to produce NP 574 
matrix components collagen type II, aggrecan and chondroitin sulphate. The 575 
deposition of this matrix was localised immunohistochemically to the clusters of 576 
MSCs visualised, indicating that the MSCs themselves were responsible for the 577 
matrix synthesis; this is in agreement with previous studies [17,20,39]. Despite this, a 578 
major concern for the clinical translation of stem cell therapy for the treatment of IVD 579 
degeneration is a lack of control over the differentiation capacity of these cells 580 
following injection into nucleus pulposus tissue [27]. In addition, the location of these 581 
cells following injection is crucial since MSC leakage followed by undesirable bone 582 
formation has been reported previously as a potential side effect of this therapeutic 583 
strategy [26]. The incorporation of MSCs within the L-pNIPAM-co-DMAc hydrogel 584 
during the liquid phase for delivery, is advantageous as it ensures the 585 
interconnecting porous hydrogel network is able to assemble around the cells. This 586 
ensures that in the initial weeks following injection that the cells are maintained 587 
within the injection site and that the microenvironment of the hydrogel itself will be 588 
the first structural influence on the differentiation capacity of the MSCs. This gives a 589 
greater potential control over the differentiation and location of the delivered 590 
regenerative cells. We have previously demonstrated in vitro that MSCs incorporated 591 
into L-pNIPAM-co-DMAc hydrogel and cultured under hypoxic conditions induces 592 
differentiation of MSCs into NP like cells without the need for additional 593 
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chondrogenic inducing medium or growth factors [23]. Here, we have shown that 594 
cells incorporated into L-pNIPAM-co-DMAc hydrogel and injected into NP explants 595 
were shown to produce NP matrix components: collagen type II; aggrecan and 596 
chondroitin sulphate. We are unable to ascertain whether the matrix deposition itself 597 
is from the delivered MSCs or native NP cells, it is most likely to be a combination of 598 
both since positive cells and deposited matrix which compositionally reflects native 599 
NP tissue, was observed both within the hydrogel itself and surrounding the 600 
hydrogel/tissue interface. Thus the translation of our previous in vitro results within 601 
an ex vivo NP tissue explant model demonstrated here, offers significant promise for 602 
the efficacy of this therapeutic strategy in the delivery of MSCs for the repair and 603 
regeneration of the NP as a future treatment of IVD degeneration. A short coming of 604 
the current study is that commercial MSCs were utilised, thus future investigations 605 
should be conducted to assess the differentiation of MSCs from a large cohort of 606 
human patients to determine patient variability and age of patients which can be 607 
utilised for such a therapy. 608 
 609 
4.2. Evaluation of mechanical properties to act as a support scaffold: 610 
The NP is regarded as a viscoelastic material, exhibiting both fluid and solid like 611 
behaviours [50]. It has been well documented that the viscoelasticity of NP tissue 612 
changes with ageing and degeneration, exhibiting a more 'solid-like' than 'fluid-like' 613 
behavior, reflected by a decreased tan� [51]. One of the hallmarks of IVD 614 
degeneration is a reduction in the overall proteoglycan content [7] resulting in 615 
reduced tissue hydration [4,52,53]. The injection of a hydrogel biomaterial, defined 616 
as a 3D hydrated crosslinked polymeric network, has therefore been hypothesised 617 
as an appealing strategy to restore NP tissue hydration and thus potentially regain 618 
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some of the viscoelastic NP material properties [54,55]. The significant increase in 619 
hydration degree of NP tissue explants following 6 weeks where acellular and hMSC 620 
incorporated L-pNIPAM-co-DMAc hydrogel was injected, provides promising 621 
evidence to suggest that the L-pNIPAM-co-DMAc hydrogel material itself is 622 
compositionally advantageous to the overall NP tissue hydration. The benefits of 623 
which would be even more apparent within degenerate tissue. Despite the increased 624 
hydration degree no significant difference in the G', G'' or the tan� were observed 625 
regardless of whether hMSCs or L-pNIPAM-co-DMAc hydrogel were injected. This is 626 
likely due to the fact that the NP tissue explant controls used in this this study were 627 
not experimentally manipulated to be degenerate; thus the fact that there is no 628 
statistical difference in the viscoelastic parameters assessed between the different 629 
experimental groups, indicates that both hMSC and L-pNIPAM-co-DMAc hydrogel 630 
injected NP tissue explants display similar biomechanical properties to native NP 631 
tissue. A limitation that should be considered however is that in this study the NP 632 
tissue explants were statically cultured within a semi-constrained Perspex ring 633 
culture system, therefore the biomechanical properties of the explant NP tissue is 634 
likely to be different from native NP tissue found within the body[49,56].  635 
Loading of whole bovine collagenase digested IVDs injected with L-pNIPAM-co-636 
DMAc hydrogel, demonstrated a significant recovery of structural properties, 637 
completely regaining pre-digested levels of disc stiffness. The full recovery of disc 638 
mechanical response following hydrogel injection, shown in this study, is a highly 639 
promising result, providing supporting evidence that the hydrogel could offer a 640 
significant and near immediate structural benefit to degenerate IVDs. 641 
Unfortunately modelling degeneration in the disc is problematic, and whilst 642 
collagenase digestion targets the collagen matrix within the disc the proteoglycan 643 
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components would still be non-digested. However as the collagen matrix forms the 644 
interconnecting network which holds the proteoglycan proteins in place, it was 645 
observed that the majority of collagenase digested discs generated large voids both 646 
macro and microscopically mimicking at least in part morphological features of 647 
degeneration. A limitation of the current study was that digestion of the discs using 648 
collagenase did not always induce digestion (4 out of 10 discs) and these samples 649 
failed to show any mechanical response. Therefore when performing the hydrogel 650 
injection following collagenase digestion, discs were carefully examined to ensure 651 
voids were visible prior to hydrogel insertion. Following loading, histological analysis 652 
demonstrated collagenase digested voids were filled with hydrogel, in all discs 653 
investigated. 654 
The reduced stiffness of collagenase digested discs and subsequent recovery 655 
following the introduction of the L-pNIPAM-co-DMAc hydrogel system may initially 656 
seem counter intuitive. Damage and degeneration of the NP expected to reduce 657 
‘fluid-like’ behaviour of the disc in favour of stiffer, ‘solid-like’ behaviour [4,51,53]. The 658 
collagenase digestion process resulted in the creation of voids or fissures within the 659 
NP, as evidenced by macro and microscopic imaging of tissues, but minimal 660 
structural damage to the AF. The result, in vitro, is a disc which maintains its original 661 
height yet contains easily compressible voids, resulting in reduced bulk stiffness. 662 
More significant breakdown of disc tissue or full or partial excision of the disc nucleus, 663 
particularly when combined with long term, continuous pressure on the IVD in vitro 664 
[57] is liable to compress voids, reducing disc height and resulting in a thin disc of 665 
mostly AF tissue, which is stiffer than that of the NP [58]. This non-linear variation in 666 
disc stiffness with degeneration grade has previously been observed in torsion, 667 
flexion and bending [59,60]. When comparing stiffness of moderately degenerate 668 
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discs compressed in vitro to degenerate discs in vivo it may be more accurate to look 669 
at the results in terms of potential to lose disc height, an important biomarker of disc 670 
degeneration [23-27]. 671 
Interestingly, significantly lower energy dissipation was observed in groups injected 672 
with the needle: sham injected; collagenase digested; and collagenase digestion 673 
followed by hydrogel injection, compared with healthy whole bovine IVDs. In contrast 674 
Michalek & Iatridis, (2012) observed no apparent difference in pressurization testing 675 
following needle puncture of bovine motion segments [61]. Interestingly however the 676 
study by Michalek & Iatridis (2012) induced a 10mm deep defect within the AF which 677 
would not have lead to puncture of the NP unlike the current study where needle 678 
puncture was performed to the centre of the disc and thus into the NP region [61]. 679 
Furthermore the loading rate investigated by Michalek & Iatridis, (2012) was 680 
considerably lower (0.1Hz) compared to the 2Hz used in the present study [61]. In 681 
the present study these dynamic parameters were selected to mimic that of walking 682 
in the human spine to enable a functional assessment of the treatment methods. The 683 
loss in energy disapation seen in the current study following needle puncture through 684 
the AF and into the NP together with the results of Carragee et al., 2009, suggests 685 
that the needle puncture itself in healthy IVDs may be the key initiator of discs losing 686 
tissue functionality, likely due to a loss in the pressure of the IVD [62]. However, as 687 
the degenerate human disc will already have a reduced energy dissipation capacity 688 
due to matrix degradation and presence of fissures [51,63,64]. The delivery of the L-689 
pNIPAM-co-DMAc hydrogel system via needle injection, is not likely to initiate any 690 
further loss in energy dissipation but will provide an immediate mechanical and 691 
clinical benefit in terms of IVD stabilisation, to what is likely to be, at the time of 692 
patient treatment, a mechanically dysfunctional tissue.  693 
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The injection of acellular L-pNIPAM-co-DMAc hydrogel injection did not recover 694 
energy dissipation to pre-digested levels; however the energy dissipation 695 
functionality is reliant on the unique pressurised environment of the intact IVD [65], 696 
therefore it is unlikely that the implantation of a biomaterial alone would provide this 697 
biomechanical function immediately. It is hypothesised that over time as the L-698 
pNIPAM-co-DMAc hydrogel integrates with surrounding NP tissue, whilst the 699 
delivered MSCs simultaneously repair and regenerate a biologically functioning NP 700 
matrix to fill in any potential fissures, that the pressurised environment and energy 701 
dissipation function of the IVD will be restored.     702 
The mechanical benefit of hydrogel injection within IVDs has been previously 703 
reported, including the restoration of the load transmission [36] and re-established 704 
disc height maintained over 0.5 million loading cycles within a bovine organ culture 705 
model [15], however in both cases, nucleotomy was required for hydrogel 706 
implantation and the incorporation and delivery of cells was not investigated. 707 
Recently Balkovec et al., 2016 reported the restoration of segmental kinematics to 708 
pre injury state in IVDs with disc height loss, following hydrogel injection, within an ex 709 
vivo porcine cervical spine model; however again nucleotomy was required to inject 710 
the hydrogel, the incorporation and delivery of cells was not investigated [13] and the 711 
immediate mechanical restoration of the hydrogel was not maintained following 712 
cyclic loading [14].  713 
The development of a biomaterial which offers the ability to safely deliver and 714 
differentiate cells, without the use of additional growth factors, as well as providing 715 
mechanical stabilisation, has so far not been achieved. Here, we demonstrate that 716 
the L-pNIPAM-co-DMAc hydrogel can be delivered by minimally invasive injection 717 
into collagenase digested whole bovine IVDs. Where it fills micro and macro fissures, 718 
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is maintained within the disc during loading and provides immediate mechanical 719 
stabilisation with improved disc stiffness back to non-digested levels, without the 720 
need for prior removal of the NP tissue. Future investigations are required to assess 721 
the fatigue properties of the hydrogel following prolonged cyclic loading. The 722 
promising results displayed here suggest that the L-pNIPAM-co-DMAc hydrogel 723 
could provide a treatment strategy which requires a less invasive surgical 724 
intervention, in regards to removal of native tissue, which may promote better tissue 725 
integration and tissue functionality. Moreover the ability to safely deliver and promote 726 
NP differentiation of MSCs within the L-pNIPAM-co-DMAc hydrogel system also 727 
provides the opportunity to biologically repair the disc as well as providing 728 
mechanical stability.  729 
4.3. Treatment design strategy tailored for stage of degeneration. 730 
Our improved understanding of the underlying pathogenesis of IVD degeneration 731 
over recent years and the consequential morphological changes that occur should 732 
be conveyed in our treatment design strategies [21,22]. It is possible that clinicians 733 
could be presented with a variety of treatment options, both cellular and acellular, in 734 
order to deliver the most efficacious, safe and cost effective treatment for the stage 735 
of degeneration [21]. Of course clinical translation is reliant on the detection and 736 
diagnosis of patients with early to mid-stages of IVD degeneration; however recent 737 
advances in quantitative MRI imaging give future promise to this possibility [66]. 738 
Future investigations into the survival and differentiation of MSCs within the hostile 739 
environment of a severely degenerate IVD are crucial in determining the success of 740 
stem cell intervention for these patients. Additionally hydrogel containment and 741 
mechanical stability within severely degenerate IVDs, where annular fissures, 742 
osteophytes and endplate fractures may be clinically present, must also be 743 
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investigated to assess whether hydrogels can offer clinical benefit for late stage IVD 744 
degeneration.  The results of these investigations, in combination with the design of 745 
suitable biomaterials and diagnostic techniques will determine the future possibility of 746 
personalized therapies for IVD degeneration. 747 
5. Conclusion 748 
Here, we have investigated the efficacy of a range of treatment options: hMSCS 749 
injected alone, acellular L-pNIPAM-co-DMAc and hMSCs incorporated within the L-750 
pNIPAM-co-DMAc hydrogel, injected into bovine NP tissue explants. Demonstrating 751 
that hMSCs injected alone or incorporated within the L-pNIPAM-co-DMAc hydrogel 752 
are able to differentiate and produce NP matrix components, thus providing 753 
compelling evidence in support of cell delivery for NP matrix repair. Additionally we 754 
have demonstrated immediate mechanical stabilisation with the injection of acellular 755 
L-pNIPAM-co-DMAc hydrogel into whole bovine IVDs, demonstrating a potential 756 
clinical benefit even in the absence of cells. The delivery of the L-pNIPAM-co-DMAc 757 
hydrogel system via minimally invasive 26 gauge needle injection and its ability to fill 758 
micro fissures, without the removal of the existing NP tissue, provides the 759 
opportunity to target symptomatic patients in early to mid-stages of degeneration. 760 
The use of a combined cellular and mechanical repair approach is particularly 761 
promising since it is hypothesised that the L-pNIPAM-co-DMAc hydrogel, could 762 
restore disc height, thus providing immediate pain relief, whilst delivery of MSCs 763 
provides gradual regeneration.  764 
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Figure Legends: 785 
Figure 1: Photomicrographs of haematoxylin & eosin stain, Hoechst staining and 786 
green fluorescent protein CFSE positive cells (shown inset for hMSC and hMSC + 787 
Hy NP tissue explants) in the injection sites of bovine nucleus pulposus tissue 788 
following 48 hours, 2, 4 and 6 weeks in culture. Magnified images of native NP cells, 789 
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stained with Hoechst, surrounding acellular hydrogel, shown inset to aid visualisation. 790 
White arrows on acellular Hy images indicate cells, black arrows on H&E images 791 
indicate hydrogel/tissue interface, red arrows on H&E images for hMSC + Hy 792 
indicate cells within hydrogel. Media injected control tissue (Control), CFSE positive 793 
hMSC injected alone (Injected hMSC), L-pNIPAM-co-DMAc hydrogel injected 794 
without cells (Acellular Hy) and hMSC incorporated into L-pNIPAM-co-DMAc 795 
hydrogel injected (hMSC+ Hy). Scale bar = 50 μm or 100μm. 796 
Figure 2: Immunohistochemical detection of caspase 3 to assess cell viability after 797 
48 hours, 2, 4 and 6 weeks in culture. Percentage immunopositivity was calculated 798 
(A). Photomicrographs representative of caspase 3 immunopositivity in tissue 799 
explants at 48 hours and 6 weeks post injection (B). Back arrows indicate positively 800 
stained cells and white arrows indicate negatively stained cells. Scale bar = 100μm. 801 
Figure 3: Scanning Electron Microscopy (SEM) of media injected control (Control), 802 
hMSC injected alone (hMSC), Acellular L-pNIPAM-co-DMAc hydrogel injected 803 
(Acellular Hy) and hMSC incorporated within L-pNIPAM-co-DMAC hydrogel injected 804 
(hMSC + Hy) NP tissue explants following 48 hours and 6 weeks in culture. Enlarged 805 
images of native NP cells (control), hMSCs (hMSCs injected alone) and cells within 806 
hydrogel region (Acell 6 weeks, hMSC + Hy 48 hours and 6 weeks) shown inset for 807 
visualisation. White arrows indicate native NP cells within Control NP explants and 808 
presence of hMSCs within hMSC injected alone NP explants. Blue arrows indicate 809 
NP tissue/hydrogel interface, demonstrating integration of hydrogel with surrounding 810 
NP tissue. Scale bar 50µm. 811 
Figure 4: Mechanical Analysis of bovine explant NP tissue using dynamic 812 
mechanical analysis (A,B,C). (A) Elastic modulus (G'), (B) loss modulus (G'') and (C) 813 
35 
 
Tan Delta (tan�) at 2.5Hz after 6 weeks in culture. (D) Calculated hydration degree 814 
of bovine explant tissue throughout 6 weeks in culture. Media injected control (con), 815 
hMSC injected alone (hMSC), acellular L-pNIPAM-co-DMAc injected (Acell Hy) and 816 
hMSC icorporated into L-pNIPAM-co-DMAc injected (hMSC + Hy). (*) Indicates 817 
statistical significance compared to controls at each timepoint (D) (*p = ≤0.05). 818 
Figure 5: Histological evaluation of bovine NP tissue explants using Alcian blue (AB) 819 
for proteoglycan deposition and Masson trichrome (MT) for collagen deposition after 820 
48 hours, 2, 4 and 6 weeks in culture. Media injected control tissue (control), hMSCs 821 
injected alone (hMSC), Acellular L-pNIPAM-co-DMAc injected (Acellular Hy) and 822 
hMSCs incorporated within L-pNIPAM-co-DMAc hydrogel injected (hMSC + Hy). 823 
Black arrows indicate positively stained cells, red arrows indicate negatively stained 824 
cells and orange arrows indicate hydrogel/NP tissue interface. Magnified images of 825 
representative cells shown inset for visualisation. Scale bar = 100 μm. 826 
Figure 6: Immunohistochemical detection of NP matrix markers collagen type II, 827 
aggrecan and chondroitin sulphate in bovine NP tissue explants. Representative 828 
photomicrographs after 48 hours, and 6 weeks in culture. Black arrows demonstrate 829 
positively stained cells and green arrows demonstrate negatively stained cells. 830 
Enlarged immunopositive cells shown inset for visualisation. Scale bar = 100 μm. 831 
Figure 7: Mechanical analysis of whole bovine IVDs that were healthy, stabbed with 832 
21G needle (sham), collagenase digested or collagenase digested followed by 833 
hydrogel injection (hydrogel). Measured parameters include: (A) Young’s Modulus, 834 
(B) % Strain and (C) Energy Dissipation. Four discs (red) from the digested group 835 
demonstrated young’s modulus and strain behaviour similar to sham injected 836 
suggesting collagenase injection had been insufficient and this was supported by the 837 
36 
 
lack of morphological evidence of collagenase digestion in these discs, thus were 838 
marked as outliers but Energy Dissipation was in line with other needle punctured 839 
discs. All replicates have been shown with outliers marked in red to demonstrate 840 
clearly the spread of replicates. Median values indicated do not include outliers 841 
within digested group. (*) Indicates significant differences between experimental 842 
groups (p=≤0.05). (D) Representative macroscopic image of whole bovine IVD 843 
following collagenase digestion (average IVD diameter 30mm). (E) Representative 844 
macroscopic image following collagenase digestion and hydrogel injection, with a 845 
green food dye incorporated within the hydrogel to aid visualisation. (F, G) 846 
Microscopic images stained with haematoxylin and eosin of whole IVD following 847 
collagenase digestion, hydrogel injection and mechanical loading. Scale bar 1000µm, 848 
200µm.    849 
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